Keywords
Sentinel lymph nodes
Lymphadenectomy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To discuss sentinel lymph node research in endometrial cancer - diagnostic accuracy and impacts on the reference hospital service in the Western Amazon. Methods: The work was carried out from a prospective, analytical, experimental study, seeking to identify sentinel lymph nodes in endometrial cancer. Results: The results found in the period from November/2020 to February/2022 identified 12 patients diagnosed with sentinel lymph node in endometrial cancer. The biggest complaint was adenocarcinoma of endometrioid origin grade 1, while for injection techniques, patent blue was evaluated, in the cervix at 3, 6 and another at 0, 3, 6 and 9h, and on the mapping carried out during the work. Conclusion: The sentinel lymph node research procedures in the present study showed that the findings of the preoperative exams, the type of operation, the postoperative diagnosis, the injection technique and the type of mapping showed several findings among the observed cases and thus each patient had to undergo a specific type of conduct until the end of treatment. In this way, it is necessary to evaluate each case specifically in order to offer the best treatment to the patient.
References
BODURTHA SAJ, et al. Sentinel lymph node assessment in endometrial cancer: a systematic review and metaanalysis. American Journal of Obstetrics & Gynecology , 2017; 216; 5; 459 –476.
BOER SM, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology.August 2016; 17 (8): 1114–1126.
CIRISANO FD JR, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74(3):385-94.
DANIELS MS. Genetic testing by cancer site: uterus. Cancer J, 2012; 18;4: 338-342.
EVERETT E, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol, 2003; 90;1:150–7.
FADY KC, et al. Divisão de Oncologia e Ginecológica, Maimonides Medical Center, Brooklyn. Nova York, 2016.
FEDERAÇÃO BRASILEIRA DAS ASSOCIAÇÕES DE GINECOLOGIA E OBSTETRÍCIA E SOCIEDADE BRASILEIRA DE CANCEROLOGIA. Carcinoma endometrial: tratamento, Diretrizes em Foco, 2011.
FERLAY J, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019; 144:1941-1953.
FEDERAÇÃO INTERNACIONAL DE GINECOLOGIA E OBSTETRÍCIA (FIGO). FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014; 125;2: 97-8.
FOLEY K, LEE RB. Surgical complications of obese patients with endometrial carcinoma. Gynecol Oncol,1990; 392: 171–4.
HAN G, et al. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF1beta. Int J Gynecol Pathol, 201;5 34;4:323-333.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2020: Incidência de Câncer no Brasil. Rio de Janeiro, 2019; 120.
INSTITUTO NACIONAL DO CÂNCER (INCA). 2014. Disponível em: http:// www.inca.gov.br/estimativa/2014/sintese-de-resultados-comentarios. Acessado em: 25 set. 2022.
JEMAL A, et al. Global cancer statistics. CA Cancer J Clin., 2011; 61: 69-90.
KHOURY-COLLADO F, et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes.Gynecol Oncol., 2011; 122: 251-4.
MELO AFB, et al. Estudo Prospectivo Randomizado comparando o Azul Patente e o Azul de Metileno na indentificação do Linfonodo Sentinela em pacientes com Câncer de Mama. In: Congresso de Pesquisa, Ensino e Extensão da UFG (CONPEEX), Goiânia. Anais eletrônicos do XIV Seminário de Iniciação Cientifica [CD-ROM]. Goiânia: UFG, 2006; 3.
MORICE P, et al. Endometrial cancer. Lancet, 2016; 387(10023):1094–1108.
MUTCH DG. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology, 2009; 115(3): 325–328.
NADEEM RA, The Increasing Credibility of Sentinel Lymph Node Mapping in Endometrial Cancer. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 2012; 100: 65.
ORGANIZAÇÃO DAS NAÇÕES UNIDAS. Agency for Research on Cancer. Cancers of the female reproductive tract. WORLD cancer report iarc Press Lyon, 2003; 215.
ORELLANA HR, et al. Cáncer de endometrio: experiencia de 10 años em el hospital San Juan de Dios. Rev. chil. obstet. Ginecol, 2013; 78.
PERES A, BARRANGER E. Arguments contre le ganglion sentinelle dans le cancer de l’endomètre: les arguments en sa défaveur Gynécologie Obstétrique & Fertilité, 2012; 40:264– 26.
ROCHA LLS, et al. Linfonodo sentinela no câncer de endométrio: Revisão narrativa. Revista Eletrônica Acervo Saúde / Electronic Journal Collection Health (REAS/EJCH), 2019; 11(5): 302.
SCUCCES M. Epidemiología del carcinoma de endometrio. Rev Obstet Ginecol Venez., 2010; 70(1): 37-41.
SIEGEL RL, MILLER KD. Estatísticas de câncer, 2017. CA Cancer J Clin., 2017; 67: 7-30.
ZHANG Y, WANG J. Controversies in the Management of Endometrial Carcinoma. Corporation Obstetrics and Gynecology International, 2010; 16.